{"id":"https://openalex.org/W7163594882","doi":null,"title":"[BRAF-Mutant Solid Tumor].","display_name":"[BRAF-Mutant Solid Tumor].","publication_year":2026,"publication_date":"2026-05-01","ids":{"openalex":"https://openalex.org/W7163594882","pmid":"https://pubmed.ncbi.nlm.nih.gov/42237509"},"language":"ja","primary_location":{"id":"pmid:42237509","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42237509","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064272098","display_name":"Yoichi Naito","orcid":"https://orcid.org/0000-0002-8490-9064","observed_orcids":["https://orcid.org/0000-0002-8490-9064"]},"institutions":[{"id":"https://openalex.org/I4210145079","display_name":"National Cancer Center Hospital East","ror":"https://ror.org/03rm3gk43","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210145079"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Yoichi Naito","raw_affiliation_strings":["Dept. of General Internal Medicine, National Cancer Center Hospital East"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of General Internal Medicine, National Cancer Center Hospital East","institution_ids":["https://openalex.org/I4210145079"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5064272098"],"corresponding_institution_ids":["https://openalex.org/I4210145079"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"53","issue":"5","first_page":"332","last_page":"336"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.8600000143051147},{"id":"https://openalex.org/keywords/braf-v600","display_name":"BRAF V600","score":0.8709999918937683},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8870000243186951},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.8069999814033508},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/braf-inhibitor-resistance","display_name":"BRAF inhibitor resistance","score":0.6790000200271606},{"id":"https://openalex.org/keywords/raf-dimerization","display_name":"RAF dimerization","score":0.9900000095367432},{"id":"https://openalex.org/keywords/pan-raf-inhibitor","display_name":"pan-RAF inhibitor","score":0.8700000047683716},{"id":"https://openalex.org/keywords/erk-inhibitor","display_name":"ERK inhibitor","score":0.9020000100135803},{"id":"https://openalex.org/keywords/braf-mutant-colorectal-cancer","display_name":"BRAF-mutant colorectal cancer","score":0.7440000176429749},{"id":"https://openalex.org/keywords/braf-mutant-melanoma","display_name":"BRAF-mutant melanoma","score":0.8880000114440918},{"id":"https://openalex.org/keywords/basket-trials","display_name":"basket trials","score":0.6679999828338623},{"id":"https://openalex.org/keywords/tumor-agnostic-therapy","display_name":"tumor-agnostic therapy","score":0.7960000038146973},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6967999935150146},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6798999905586243},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.607200026512146},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.5767999887466431},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5515999794006348},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5339999794960022},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.49619999527931213},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.44839999079704285},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.427700012922287},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.41040000319480896},{"id":"https://openalex.org/C2776470698","wikidata":"https://www.wikidata.org/wiki/Q21851559","display_name":"V600E","level":4,"score":0.40950000286102295},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.4075999855995178},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3991999924182892},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.3711000084877014},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36480000615119934},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.33149999380111694},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3100000023841858},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.2937000095844269},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.2903999984264374},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.28999999165534973},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2897999882698059},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.2879999876022339},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.2865999937057495},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.2721000015735626},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.2628999948501587},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.258899986743927}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:42237509","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42237509","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2326876692","https://openalex.org/W2789665281","https://openalex.org/W7170171616","https://openalex.org/W2952075276","https://openalex.org/W2399908138","https://openalex.org/W4225136170","https://openalex.org/W2065208438","https://openalex.org/W2400942929","https://openalex.org/W1543819161","https://openalex.org/W6911681197"],"abstract_inverted_index":{"BRAF":[0,28,70,94,106,151,199,205],"is":[1,18],"a":[2,8,33],"serine/threonine":[3],"kinase":[4],"that":[5],"functions":[6],"as":[7,20,134,177],"key":[9],"component":[10],"of":[11,35,60,93,119,123,158,165,186,195],"the":[12,53,61,117,163,184,193,203],"RAS/RAF/MEK/ERK":[13],"(MAPK)":[14],"signaling":[15,84],"pathway":[16,63],"and":[17,47,64,68,86,96,109,139,180,221],"recognized":[19],"an":[21],"important":[22],"oncogenic":[23],"driver":[24],"across":[25,189],"multiple":[26],"cancers.":[27],"mutations":[29,71],"are":[30,72,224],"detected":[31],"in":[32,57,103,130],"variety":[34],"malignancies":[36,132],"including":[37,168,218],"melanoma,":[38,108],"thyroid":[39,140],"cancer,":[40,42,46],"colorectal":[41,145],"non-small":[43,135],"cell":[44,136],"lung":[45,137],"biliary":[48],"tract":[49],"cancer.":[50,141],"Among":[51],"them,":[52],"V600":[54],"mutation":[55],"results":[56],"constitutive":[58],"activation":[59,157],"MAPK":[62],"promotes":[65],"tumor":[66,190],"growth":[67],"survival.":[69],"currently":[73],"classified":[74],"into":[75],"three":[76],"functional":[77],"classes":[78],"(class":[79],"1-3)":[80],"according":[81],"to":[82,150,155,162,227],"their":[83],"mechanisms":[85],"dependency":[87],"on":[88],"RAS":[89],"activation.":[90],"The":[91],"development":[92,164,226],"inhibitors":[95,98,200,220,223],"MEK":[97],"has":[99,115,126],"significantly":[100],"improved":[101],"outcomes":[102],"patients":[104],"with":[105,112],"V600-mutant":[107],"combination":[110,166],"therapy":[111],"these":[113,229],"agents":[114],"become":[116],"standard":[118],"care.":[120],"Clinical":[121],"activity":[122],"BRAF/MEK":[124],"inhibition":[125],"also":[127],"been":[128],"demonstrated":[129,183],"other":[131],"such":[133,176],"cancer":[138,146],"In":[142,171],"contrast,":[143],"BRAF-mutated":[144],"shows":[147],"limited":[148],"sensitivity":[149],"inhibitor":[152],"monotherapy":[153],"due":[154],"feedback":[156],"EGFR":[159,169],"signaling,":[160],"leading":[161],"strategies":[167],"inhibitors.":[170],"recent":[172],"years,":[173],"basket":[174],"trials":[175],"VE-BASKET,":[178],"NCI-MATCH,":[179],"ROAR":[181],"have":[182],"efficacy":[185],"BRAF-targeted":[187],"therapies":[188],"types,":[191],"supporting":[192],"concept":[194],"tumor-agnostic":[196],"treatment.":[197],"Current":[198],"mainly":[201],"target":[202],"active":[204],"monomer;":[206],"however,":[207],"resistance":[208,230],"mediated":[209],"by":[210],"RAF":[211],"dimerization":[212],"frequently":[213],"occurs.":[214],"Novel":[215],"therapeutic":[216],"approaches":[217],"pan-RAF":[219],"ERK":[222],"under":[225],"overcome":[228],"mechanisms.":[231]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-06-05T00:00:00"}